Immatics NV: Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Website:
Address:
Paul-Ehrlich-Str. 15
Tübingen, 72076
Germany

Company Participants at 2nd Solebury Trout Virtual Global Healthcare Conference Series

Harpreet Singh, PhD
Immatics Biotechnologies GmbH , CEO
Dr Harpreet Singh co-founded Immatics in 2000. Since then he has served as Managing Director and Chief Scientific Officer of Immatics Biotechnologies GmbH, helping to grow the company from a start-up to an established biotech. He is dedicated to translating pioneering scientific discoveries into highly innovative cancer immunotherapeutics with clinical utility. Dr Singh has played a leading role in raising over US$200m of venture capital funding over several financing rounds. Since 2015, Dr Singh is President & CEO of Immatics US, Inc. overseeing all operations of Immatics in Houston, Texas as to develop next-generation Adoptive Cell Therapies (ACT). He contributed significantly to raising the necessary funding including a $20m CPRIT grant by the State of Texas. Dr Singh is the inventor on numerous patents and patent applications and has co-authored approx. 30 publications in prestigious peer-reviewed journals including Nature Medicine, Nature Biotechnology, Lancet Oncology and Journal of Experimental Medicine, Brain and Blood. A scholar of Prof. Hans-Georg Rammensee, Dr Singh completed his academic studies by gaining a Ph.D. in immunology at the University of Tuebingen, Germany.

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.